STORM Therapeutics, a Cambridge biotech, has raised $56M in a Series C round backed entirely by existing investors including Pfizer Ventures and M Ventures. The company has also dosed the first patient in a Phase 2 trial of STC-15, the world's first RNA-modifying enzyme inhibitor to reach human clinical trials. STC-15 targets METTL3, an enzyme that methylates mRNA and is exploited by certain cancers to maintain malignant cell proliferation. Phase 1 results showed durable tumour regression across multiple sarcoma subtypes. The Phase 2 trial focuses on selected sarcoma indications and is designed to support an accelerated regulatory approval pathway. STC-15 is also being evaluated in combination with a PD-1 inhibitor across several other cancer types.
Sort: